Barclays has initiated coverage on Viatris Inc (VTRS) with an Overweight rating, marking the firm's first assessment of the company. The action, taken on December 8, 2025, reflects Barclays' evaluation of Viatris' business dynamics and growth prospects.
Viatris, a global healthcare company headquartered in Canonsburg, Pennsylvania, provides a range of pharmaceutical products. The firm operates across developed markets, Greater China, JANZ, and emerging markets, employing approximately 32,000 people. Its market cap stands at $11.7 billion, with a current price of $11.53 and a trailing twelve months EPS of -2.91.
Upcoming earnings reports are scheduled for May 6, 2026, and August 5, 2026, with estimated EPS of $0.59 and $0.65, respectively. The latest earnings performance indicates a Q3 2025 EPS of $0.67, surpassing estimates by 5.8%. Analyst consensus currently leans toward a Buy, with 3 Strong Buy, 6 Buy, 6 Hold, and 2 Sell ratings among 17 total analysts.
This update provides insight into Viatris' standing in the pharmaceuticals sector, as analyst ratings can evolve with new information and market conditions.